Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2019)

DiaMedica Therapeutics' Research & Development history spans 2 years, with the latest figure at $1.8 million for Q4 2019.

  • For Q4 2019, Research & Development rose 24.19% year-over-year to $1.8 million; the TTM value through Dec 2019 reached $7.9 million, up 74.7%, while the annual FY2025 figure was $24.6 million, 29.16% up from the prior year.
  • Research & Development reached $1.8 million in Q4 2019 per DMAC's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.6 million in Q1 2019 to a low of $791000.0 in Q1 2018.